Delta Asset Management LLC TN continued to hold its position in Intrexon Corporation (NYSE:XON) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,000 shares of the biotechnology company’s stock at the end of the second quarter. Delta Asset Management LLC TN’s holdings in Intrexon Corporation were worth $120,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in XON. Vanguard Group Inc. raised its position in Intrexon Corporation by 5.6% in the first quarter. Vanguard Group Inc. now owns 4,286,362 shares of the biotechnology company’s stock worth $84,954,000 after buying an additional 226,090 shares during the period. Iridian Asset Management LLC CT raised its position in Intrexon Corporation by 2.4% in the first quarter. Iridian Asset Management LLC CT now owns 3,853,274 shares of the biotechnology company’s stock worth $76,372,000 after buying an additional 91,565 shares during the period. State Street Corp boosted its stake in Intrexon Corporation by 34.0% in the first quarter. State Street Corp now owns 2,707,242 shares of the biotechnology company’s stock worth $53,664,000 after buying an additional 687,406 shares in the last quarter. First Trust Advisors LP boosted its stake in Intrexon Corporation by 15.9% in the first quarter. First Trust Advisors LP now owns 1,160,308 shares of the biotechnology company’s stock worth $22,997,000 after buying an additional 158,964 shares in the last quarter. Finally, Norges Bank acquired a new stake in Intrexon Corporation during the fourth quarter worth $17,300,000. Hedge funds and other institutional investors own 84.38% of the company’s stock.
Shares of Intrexon Corporation (XON) opened at 19.65 on Friday. Intrexon Corporation has a 52-week low of $17.70 and a 52-week high of $32.90. The firm’s market cap is $2.37 billion. The stock’s 50 day moving average price is $22.92 and its 200-day moving average price is $21.94.
Intrexon Corporation (NYSE:XON) last issued its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.05. Intrexon Corporation had a negative net margin of 60.63% and a negative return on equity of 19.04%. The business had revenue of $54.40 million for the quarter, compared to analysts’ expectations of $57.17 million. During the same quarter last year, the company posted ($0.42) earnings per share. The company’s quarterly revenue was up 3.6% compared to the same quarter last year. On average, equities research analysts anticipate that Intrexon Corporation will post ($0.87) earnings per share for the current fiscal year.
A number of analysts have weighed in on XON shares. Zacks Investment Research upgraded Intrexon Corporation from a “hold” rating to a “buy” rating and set a $24.00 price target on the stock in a research note on Tuesday, May 2nd. BidaskClub upgraded Intrexon Corporation from a “sell” rating to a “hold” rating in a research note on Thursday, June 22nd. Finally, Northland Securities set a $30.00 price target on Intrexon Corporation and gave the company a “buy” rating in a research note on Monday, August 7th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $40.50.
In related news, Director Dean J. Mitchell purchased 5,000 shares of Intrexon Corporation stock in a transaction dated Friday, August 11th. The shares were acquired at an average price of $18.33 per share, with a total value of $91,650.00. Following the completion of the transaction, the director now owns 18,103 shares of the company’s stock, valued at approximately $331,827.99. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders have bought 7,094 shares of company stock worth $129,593 in the last ninety days. Corporate insiders own 55.10% of the company’s stock.
About Intrexon Corporation
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with MarketBeat.com's FREE daily email newsletter.